Condition: Asthma With Eosinophilic Phenotype · Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
This description comes directly from the study's public registry record.
Xiaopeng Wang · +086-18260387118 · xiaopeng.wang@hengrui.com
Always discuss trial participation with your own doctor first.
| West China School of Medicine West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06653322